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Extensive research is ongoing that concentrates on finding therapies to enhance CNS regeneration after spinal cord injury (SCI)
and to cure paralysis. This review sheds light on the role of the FGFR pathway in the injured spinal cord and discusses various
therapies that use FGFR activating ligands to promote regeneration after SCI. We discuss studies that use peripheral nerve grafts or
Schwann cell grafts in combination with FGF1 or FGF2 supplementation. Most of these studies show evidence that these therapies
successfully enhance axon regeneration into the graft. Further they provide evidence for partial recovery of sensory function
shown by electrophysiology and motor activity evidenced by behavioural data. We also present one study that indicates that
combination with additional, synergistic factors might further drive the system towards functional regeneration. In essence, this
review summarises the potential of nerve and cell grafts combined with FGF1/2 supplementation to improve outcome even after
severe spinal cord injury.
1. Introduction
1.1. Spinal Cord Injury. Spinal cord injury (SCI) is a severe
condition with an annual incidence of 1000 people each year
in the UK and Ireland. This results in high costs that are cur-
rently at m1 billion per annum in the UK and Ireland (http://
www.spinal-research.org/research-matters/spinal-cord-inju-
ry/facts-and-figures/). While there is good regeneration of
peripheral nerves, injury to the central nervous system (CNS)
is permanent since injured CNS axons do not regenerate
long distances back to their original targets. Nonetheless,
there is a certain degree of spontaneous repair, for example,
via differentiation of precursor cells, axon sprouting, and
building of new spinal circuits [1, 2]. These are areas that
can be targeted by research in order to find new therapeutic
approaches to increase axon regeneration after damage to the
CNS. This review will concentrate on SCI and the function
of the fibroblast growth factor receptor (FGFR) pathway in
regeneration of injured axons.
It has been accepted that the devastating consequences of
SCI are due to the limited capacity of lesioned CNS axons
to undergo morphological and functional recovery, loss of
neurons in the epicentre [3], and a conduction block of
spared axons due to demyelination [4]. Causative factors for
the inability of CNS axons to regenerate are a combination
of factors including intrinsic and extrinsic factors. Intrinsic
factors include progrowth genes that are not expressed by
mature, injured neurons such as GAP-43 [5] and KLF7 [6]
or antigrowth genes that are expressed by mature, injured
neurons such as KLF4 [7]. Extrinsic factors are, for instance,
lack of trophic support and the presence of inhibitory glial
influences in the local environment, as reviewed by several
groups [8–11].
SCI can be caused by contusion, compression, penetra-
tion, or maceration. All injuries cause massive damage to the
spinal cord and induce a cascade of events. The immediate
reaction consists of axotomy, haemorrhage, and ischema
and then apoptosis and necrosis of cells including neurons,
oligodendrocytes, and astrocytes. Secondary effects are fur-
ther apoptosis, demyelination of axons, and the invasion
of immune cells, such as macrophages, neutrophils, and T
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cells and activation of microglia [12–14]. Subsequently, a
glial scar is formed at the injury site, which consists of
reactive astrocytes, glial progenitors, microglia, macrophages
[15, 16], fibroblasts, and Schwann cells [17, 18]. Importantly,
numerous regeneration inhibitorymolecules are found in the
scar, such a Nogo-A and chondroitin sulphate proteoglycans
(CSPGs) [19–21]. However, even though for many years
the glial scar has been believed to have detrimental effects
on axon regeneration, there is more and more evidence
emerging that show that there is also a beneficial effect of the
glial scar on axon regeneration [22]. The primary injury is
immediate and irreversible, but the secondary injury evolves
over time and provides a window of opportunity for treat-
ment.
There has been much focus of research on how to
promote regeneration of injured axons. This review focuses
on therapies that manipulate the FGFR pathway to promote
recovery after SCI.
1.2. The FGFR Pathway. The FGFR pathway is important
in development, maintenance, and regeneration of the ner-
vous system. The FGFR superfamily consists of 4 different
receptors FGFR1–4. FGFR1–3 are each found in two different
isoforms, named b and c, while FGFR4 exists only in the c
isoform [23] (Figure 1(a)). The predominant receptors in the
CNS are FGFR1 and 2. To date, 22 different FGF ligands have
been identified, whereby FGF1 and FGF2 bind all 4 receptors.
They are both secreted proteins and signal in a para- or
autocrine fashion. Downstream of FGFR1 activation is three
mayor pathways: AKT- and ERK-pathway that are activated
via FibroblastGrowth Factor Receptor Substrate 2 (FRS2) and
PLC𝛾 which is FRS2 independent [23] (Figure 1(b)). Many
therapeutic approaches aim at increasing the concentration
of either of these two ligands at the injury site and this will be
discussed in more detail below.
Further to the 22 FGF ligands NCAM, N-cadherin,
and L1 have been shown to activate the FGFR pathway in
the nervous system [24–26]. Binding of these ligands to
the FGFR1 leads to binding and activation of PLC𝛾 and
subsequently to the production of diacylglycerol and an
increase in cytosolic Ca2+ [27]. Diacylglycerol then produces
ligands that activate the endocannabinoid receptor [28].
Two endocannabinoid receptors exist; the endocannabinoid
receptor 1 (CB1) is mainly expressed in the CNS [29]. CB1 is a
7 transmembrane receptor [29–32] that can be activated by
anandamide and 2-arachidonylglycerol [33, 34]. Activation
of CB1 leads to activation of Ca2+ and K+ channels, the
PI3K pathway, and various MAPK pathways, such as ERK,
p38, and the JNK pathway. It also leads to inhibition of
cAMP production and PKA activity. It has been shown that
activation of the JNK pathway downstream of CB1 activation
converges into STAT3 activation which leads to neurite out-
growth [35, 36]. Manipulating the endocannabinoid system
downstream of the FGFR pathway is one other important
line of therapeutic research to enhance regeneration in the
CNS.
A summary of the functions of FGFR signalling at the
lesion site can be found in Figure 2.
2. Expression of FGF Ligands and Receptors in
the Nervous System
2.1. Myelinating Cells. SCI causes acute and chronic loss of
oligodendrocytes for up to a year after injury in rats and
monkeys [37, 38]. Remyelination of spared neurons would
enhance their ability to conduct action potentials efficiently.
How this happens spontaneously is currently under debate.
There is evidence for two mechanisms: (1) Schwann cells
migrate from the periphery to the site of injury [39–41]
or (2) oligodendrocyte precursor cells (OPCs) differentiate
into mature myelinating cells [42, 43]. Indeed, it is also
possible that both mechanisms act synergistically. It has
been shown that FGF2 in concert with PDGF-A, IGF-I,
and TGF-𝛽1 plays a role in remyelination after lysolecithin
induced demyelination of neurons [44]. Oligodendrocytes
and their progenitors express FGF2 and FGFR1, 2, or 3
depending on their state of progression through their lin-
eage. FGFR1 expression increases as the lineage progresses,
FGFR3 is most highly expressed in late progenitors and
then declines, and FGF2 is expressed in terminally differ-
entiated oligodendrocytes [45]. Further, oligodendrocytes
are dependent on FGF2 for differentiation and proliferation
[46] and independent of the maturation process the FGF
signalling pathway is regulating myelin growth [47]. The
regulated expression of members of the FGF family through-
out the maturation of oligodendrocytes presents an oppor-
tunity for therapeutic intervention that has not yet been ex-
plored.
2.2.Microglia. Microglia participate in the removal ofmyelin
debris and produce growth factors, including the glial cell
line derived neurotrophic factor [48], that are favourable
for neurite growth and regeneration [49]. Microglia express
FGF2 and induce increased FGF2 expression in neurons
which results in neuroprotection [50]. To our knowledge
there is no therapeutic research done on microglia with
respect to the FGF superfamily. However, this could be a
potential route for interference.
2.3. Astrocytes. Astrocytes express FGF2 which plays a role
in their differentiation [51, 52] and proliferation [53]. Fur-
thermore, it has been shown in vivo that astrocytes express
FGFR1 mRNA and protein [54–56], as well as FGFR2 mRNA
[57]. Further, it has been shown in vitro that they also
express FGFR3, however, at a lower level than FGFR1 and
2 [58]. FGFR3 expression by astrocytes has also been found
in vivo and signalling via this receptor has been associated
with repression of GFAP expression [59]. Astrocytes trans-
form after injury into reactive astrocytes. Reactive astrocytes
express and secrete higher levels of FGF2 after SCI, which
in turn promotes proliferation and survival of OPCs [60–
63]. The effect or reactive astrocytes on motoneurons is
diverse. For instance, they induce via a p75NTR dependent
mechanism oxidative stress in motoneurons and subsequent
death of the same [64]. Simultaneously, oxidative stress in
motoneurons results in FGF1 release from motoneurons
which enhances activation of astrocytes [65] which might be
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Figure 1: The FGFR signaling pathway. (a) Schematic of the structure of FGF receptors and the binding specificities of the FGF ligands. (b)
Depiction of the FGFR downstream signalling. HS: heparan sulfate; PIP2: phosphatidylinositol 4,5-bisphosphate; IP3 inositoltriphosphate;
PLC𝛾: phospholipase C; DAG: diacylglycerol; GRB2: growth factor receptor-bound protein 2; GAB1: GRB2 associated binding protein 1; Sos:
son of sevenless; MEK: MAPK/ERK kinase; MAPK: mitogen activated protein kinase; STAT: signal transducer and activator of transcription;
TFs: transcription factors.
leading to increased scar formation. Furthermore, astrocytes
have been shown in vitro to be attracted by FGF2 [66].
Since the amount and reactivity of astrocytes have been
proven essential for the quality of the scar that defines
whether it is detrimental or beneficial, we believe that
also astrocytes could be a target of FGF induced ther-
apy.
3. Expression of FGF Ligands in the Intact and
Injured Spinal Cord
3.1. Expression of FGF1 and FGF2 before and after Injury. All
cell types of the nervous system express FGF ligands and
receptors at a basal level; however, SCI results in changes
of their expression pattern which allows together with other
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Figure 2: Overview of the spinal cord lesion and cells found in the lesion with their action stimulated by FGFR signaling.
factors a limited degree of spontaneous regeneration after
SCI. Several studies confirmed that expression of FGF1 and
FGF2 in the injured cord is upregulated at the mRNA and
protein level: FGF2, but not FGF1 mRNA, is upregulated
after an incomplete thoracic contusion in spinal cord tissue
including the lesion site [78]. Furthermore, FGF2 protein has
been found upregulated after contusion in glial cells, along
blood vessels and surrounding neurons [79]. Koshinaga et
al. investigated in detail the distinct increase of FGF1 and
FGF2 in different anatomical structures and at different time
points after a photochemically induced complete destruction
of the dorsal columns of rats at T8. They propose that
FGF1 and 2 have distinct roles after SCI since they show
very differential cellular, temporal, and spatial expression
following after destruction of the dorsal columns [80]. In the
uninjured spinal cord FGF1 is expressed in the cytoplasm
of ventral motor neurons and sensory fibres in the dorsal
columns. FGF2 is expressed in astrocytic nuclei and the
cytoplasm of few neurons of the grey matter. After the lesion
they found a distinct cellular, temporal, and spatial expression
of FGF1 and FGF2, which suggests separate roles for them
in response to SCI. They investigated the expression level of
FGF1 two and five days after injury at the lesion site, above
the lesion (T4-5) and below the lesion (L1-2).They found that
two days after injury FGF1 protein was upregulated in the
ventral motor neurons and intermediate grey matter at the
lesion site. Furthermore, FGF1 protein was expressed in the
(spared) fasciculus cuneatus at T4-5, but not in the (lesioned)
fasciculus gracilis at the same level (note that the lesion was at
thoracic vertebral levels T8). However, at L1-2 FGF1 protein
expression was increased in the fasciculus gracilis, which
suggests that normally FGF1 is anterogradely transported.
This was assessed by immunohistochemistry against FGF1.
The authors do not co-stain with other markers, but draw
their conclusions from the anatomy and the morphology
of the stained structures. FGF2 protein in contrast was
unchanged 2 days after surgery but upregulated five days after
the lesion in the nucleus and cytoplasm of reactive astrocytes
at the edge of the cystic cavity and in the dorsal columns at
T4-5. In summary, there is very specific upregulation of FGF1
and 2 in distinct anatomical structures and cells.
3.2. FGF22 Signalling after Injury. It has been shown that
one mechanism of spontaneous regeneration after SCI is
formation of new intraspinal circuits in order to circumvent
the lesion site [1, 81]. New formation of circuits requires
newly formedCST collaterals to enter the cervical greymatter
and formation of synapses to new targets, for example, long
propriospinal neurons [1]. The group of Florence Bareyre
has shown that FGF22 signalling via FGFR1 and FGFR2
is essential for the formation of these new synapses [82].
They showed that FGF22 is expressed in spinal interneurons,
including a large proportion of long propriospinal neurons,
and that FGFR1 and 2 are expressed in the CST of mice.
They found that ablation of either FGF22 or one or both
of the receptors in conditional knockout mice leads to
decreased synapse formation between newly formedCST col-
laterals and propriospinal relay neurons after thoracic dorsal
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hemisection. Further, this lead to inhibited functional recov-
ery after the lesion proven by showing that the geneti-
cally altered animals performed more mistakes with their
hindlimbs on the horizontal ladder and mice had an abnor-
mal angle between the hindlimb paws and body axis as
measured on the Catwalk [82]. There is further evidence that
FGF22 has a role in synapse formation in the CNS [83].
4. Therapeutic Approaches Targeting the
FGFR Pathway
For functional regeneration axotomised axons have to grow
around or through the glial scar and form functional synapses
distal to the lesion site. One line of therapeutic research aims
at promoting axon regeneration by manipulating the FGFR
signalling pathway.
4.1. Therapies Delivering FGF1 to the Injury Site. The study
of Cheng et al. set out to ensure that the injury site is
supplemented with FGF1 for a prolonged time directly after
a complete transection injury at T8 in rats [67]. To achieve
this, they bridged the gap resulting from the removal of 5mm
of the spinal cord by using 18 fine segments of autologous
peripheral nerve implant with fibrin glue containing FGF1.
The fibrin glue was designed to provide slow release of
FGF1 [84]. To evade oligodendroglial proteins that inhibit
regeneration they aimed to transplant the nerve segments in
a way to link from the nonpermissive white matter to the
permissive grey matter, thereby rerouting descending motor
and ascending sensory pathways. However, there is no direct
evidence that they successfully achieved this. To stabilise the
lesion site the authors applied fibrin based tissue glue and
fixated the vertebrate column by dorsiflexionwiring [67].The
study has been extensively controlled by four control groups:
(1) transection only, (2) transection with removal of 5mm of
the spinal cord, (3) transection with grafting but routing the
fibres through white matter only, and (4) transection with
grafting but omission of FGF1. Two independent blinded
observers assessed the combined behavioural score and the
open-field walking score. The authors found 3 weeks after
injury and persistent throughout the 12months ofmonitoring
that the experimental group of transected, grafted, and FGF1
treated rats had flexion at the hips and knees and dorsiflexion
of the ankle, partial body weight support, absence of toe
dragging, and contact placing while the control rats (all four
groups) had fully extended, externally rotated hindlimbs.
The observed contact placing in the experimental group is
indicative of CST regeneration. To test this, they performed
retro- and anterograde tracing experiments.The authors state
that axons regenerated into the graft and beyond into the
distal host tissue; however, they only show the tracing in one
animal from the sensorimotor cortex to the lumbar section of
the spinal cord. The pictures are difficult to interpret without
a negative control; therefore, the evidence for regeneration
beyond the lesion site is not entirely convincing. Interestingly,
they state that there are cavities surrounded by glial fibrillary
acidic protein- (GFAP-) rich regions between the spinal cord
stumps in the experimental group. The group of Jerry Silver
used several years later the same approach of injury and
nerve grafting that Cheng et al. used and investigated the
rescue of bladder function. This study is discussed in detail
below. However, we would like to mention here that Jerry
Silver’s group found evidence that axons regenerate mostly at
these GFAP-rich sites from the host into the graft [76]. The
group of Cheng later investigated a possible mechanism of
the increased regeneration of peripheral nerve graft and FGF1
treated animals. They found that a peripheral nerve graft
alone increases the level of CSPGs at the junction of graft and
host tissue and in the degenerative area. However, addition of
FGF1 to the peripheral nerve graft or FGF1 treatment alone
reduced the level of CSPGs [85]: However, they did not show
if the differential level of CSPGs actually has an effect on
the regenerating axons. In summary, these data indicate that
FGF1 may modify the host-graft interface to make it more
permissive to axon regeneration.
Lee et al. 2002 used the same approach as Cheng et al. and
corroborated their earlier findings. Comparable to the origi-
nal study they observed an increase in the BBB score fromone
to seven comparing the transected, grafted, and FGF1 treated
experimental group to four control groups (laminectomy
only, transection only, FGF1 releasing matrix only, and tran-
section plus nerve graft and fibrinmatrix without FGF1) [68].
Furthermore, they reproduced the observation that there is
partial recovery of hind-paw contact-placing reflexes in the
experimental group. However, in addition to Cheng et al.
they performed electrophysiology and showed that not only
locomotor function was partially restored, but also ascending
sensory pathways. They measured somatosensory evoked
potentials (SSEPs) in the sensory cortex after stimulation of
the sciatic nerves at very high intensity (20mA).The authors
found in the injured rats four month after injury treated with
FGF1 and peripheral nerve grafts similar latencies in SSEP as
in sham operated rats, but lower amplitudes. This effect was
lost after a retransection of the spinal cord. They state that
this indicates that there were motor and sensory fibres that
grew through the bridge to form synapses on distal pathways.
However, nonspecific effects of high intensity stimulation
(e.g., stimulus spread) cannot be ruled out. Importantly, in
this study there was a control group that received the nerve
graft and fibrin matrix but no FGF1.This group did not show
improved regeneration compared to the other control groups,
which suggests that it is the combination of nerve graft and
FGF1 treatment which is needed to achieve regeneration and
reconnection. Together, Cheng et al. and Lee et al. present
evidence that the combination of nerve graft bridging and
FGF1 releasing fibrin matrix results in regeneration of some
motor and sensory fibres across the transection injury.
In contrast to peripheral nerve grafts Guest and col-
leagues used human Schwann cell grafts supplemented with
FGF1 [69]. They performed a mid-thoracic spinal cord
transection in adult athymic nude rats, a xenograft tolerant
strain. At the time of injury, they bridged the gap with a
human Schwann cell graft with or without FGF1-containing
fibrin glue placed at the injury-graft boundary. Ten days after
the injury and the grafting the dorsal surface of the guidance
channel was incised and a small segment was removed to
place a fresh aliquot of 10 𝜇L glue containing FGF1 and
reseal the opening.Thirty-five days after injury and treatment
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Table 1: Different strategies to promote regeneration using FGF1.
Species Model Therapeutic intervention Outcome Control Ref
Rat
Complete
transection at T8.
Removal of 5mm
of SC.
Autologous peripheral
nerve implant with glue
containing FGF1. Routing
of regenerative pathway
from white matter to grey
matter.
Improvement on open field
walking score from 0.5 to 3.
Axon regeneration beyond
the graft. Fewer GFAP poor
holes between the stumps.
Transection only.
Cord removal only.
White matter-to-white
bridging.
Omission of FGF1.
[67]
Rat
Complete
transection at T8.
Removal of 5mm
of SC.
Autologous peripheral
nerve implant with glue
containing FGF1.
Improvement on BBB from
1 to 7. Partial restoration of
sensory function.
Transection only,
laminectomy only.
Transection and
peripheral nerve graft
and matrix fibrin matrix
without FGF1.
Transection and FGF1
fibrin matrix.
[68]
Nude rat Mid-thoracic SCtransection.
Human Schwann cell graft
with FGF1 fibrin glue at the
injury-graft boundary and
delayed FGF1 fibrin glue at
the dorsal surface of the
guidance channel.
Axon regeneration into the
graft. Maximum
termination density closer
the host-graft interface.
Less axonal die-back.
Schwann cell graft
without FGF1. [69]
they found that grafted and FGF1 fibrin glue treated animals
showed CST axon regeneration into the graft while control
animals did not do so. Furthermore, they showed that the
maximum termination density is closer to the rostral host-
graft interface and that there is less axonal die-backmeasured
by the longitudinal spread of bulbous end terminals. The
authors offer two mechanistic hypotheses: (1) intrinsic: FGF1
is retrogradely transported in the CST and improves the
regenerative capacity of the CST. This might be feasible since
it has been shown that FGF1 is both anterogradely [80] and
retrogradely [86] transported in ascending sensory fibers
and enhances PNS regeneration [87]; (2) extrinsic: the FGF1
fibrin glue alters the host-graft boundary in a way that makes
the local environment growth permissive. In favour for this
hypothesis is the fact that FGF1 alters the behaviour of glial
cells [69] and that reactive astrocytes have been thought
of expressing high levels of FGF1 receptors [56, 57]. In
summary, Guest et al. report that human Schwann cell grafts
supplemented with FGF1 after complete transection result in
ingrowth into the graft of regenerating axons; however, there
was no evidence that axons also grew into the distal host
tissue.
Together these studies show that addition of FGF1 to
the lesion site after a complete transection and grafting of
peripheral nerve segments or human Schwann cells enhances
regeneration of axons to a limited extent.
A summary for therapeutic approaches using FGF1
delievery can be found in Table 1.
4.2. Therapies Enhancing FGF2 Concentration in the Injured
Spinal Cord. There was another approach using Schwann
cell grafts. Rat Schwann cell grafts have been combined with
FGF2 supplementation after a complete transection at T9/T10
with removal of 4mm of spinal cord in rats [70]. How-
ever, this study showed a less promising outcome than the
previously discussed study of Guest et al. In Meijs’ study,
the only difference in outcome between FGF2 supplemented
Schwann cell grafts and control Schwann cell grafts was the
increased survival of NeuN positive cells in the posterior
cord. There was no difference in the amount of white
matter sparing, axonal ingrowth into the graft, the ratio of
unmyelinated to myelinated axons and BBB score between
the experimental and the control group.However, the authors
found higher intensity of CSPG and GFAP staining. Upregu-
lated levels of GFAP positive, reactive astrocytes that secrete
CSPGs might explain the lack of regeneration since they may
inhibit any axon regeneration across the host-graft boundary.
However, this theory offered by the authors is in contrast to
later findings that show that longitudinally aligned astrocytes
may serve as substrate for growth at the injury site [22, 76].
It is quite intriguing that Schwann cell grafts with FGF1 have
such a positive outcome and Schwann cell grafts with FGF2
do not. However, there are some critical differences between
the two studies. The FGF1 study was done with human
Schwann cell grafts in nude rats and the FGF2 study was done
with rat Schwann cell grafts in Fisher rats. In the FGF1 study
they placed the FGF1 at the two graft-host tissue interfaces
while in the FGF2 study they mixed the Schwann cells with
the FGF2. Also, in the FGF1 study they added 10 days after the
injury fresh fibrin containing FGF1into the channel. This was
not done in the FGF2 study. These differences may account
for the different outcomes.
Sasha Rabchevsky pursued the effect of FGF2 upon
regeneration by using osmotic minipumps while working
in the group of Stephen Scheff [71, 72]. After a moderate
contusion injury at T10 in rats they implanted two osmotic
minipumps per animal delivering FGF2 into the lateral
ventricle and the lumbar thecal sac between 30 minutes to
one week after injury. They reported that this treatment with
FGF2 resulted in an improved BBB score of 15/16 four to six
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weeks after injury compared to control animals reaching 12/13
only [71]. Furthermore, they found that there wasmore tissue
sparing in the FGF2 treated animals compared to control
animals. They conclude that the observed effects are due to
the neuroprotective effect of FGF2, which has been reported
previously [88–96]. They later confirmed these results in a
more severe injury model [72]. In this study they observed
improvement in the BBB score from 7–10 to 10–13. However,
they did not observe improved tissue sparing or a difference
in number of astrocytes and microglia when compared to
control animals. Therefore, the authors conclude that there
is an as yet undefined mechanism of FGF2 contributing to
enhanced functional recover.
Kasai et al. injected FGF2 directly after a complete
transection at T10 into the surrounding spinal cord tissue
of rats [73]. They chose this approach over a slow releasing
method since they believe that the storage of FGF2 in
the extracellular matrix after injection should be sufficient.
Gonzalez et al. showed that FGF2 could be detected in the rat
brain four and seven days after FGF2 injection [97]. During
the six weeks in which they assessed the rats behaviourally
they found an increase in the BBB scale of the treated
rats versus untreated rats. While the control group did not
improve on the BBB scale at all and remained at a score of
zero, the FGF2 injected rats reached on average a score of
nearly six, moving two of their hindlimb joints six weeks
after complete transection. They also performed tracing
experiments with fluorogold (FG) in the spinal cord 5mm
caudal to the injury site. The animals were injected with FG
6 weeks after injury and euthanised 3 days after FG injection.
They report positive neural cell bodies in the sensorimotor
cortex and red nucleus after FG trancing. Even though the
number of FG positive cell bodies is significantly less than
in sham operated animals, the authors believe that this
indicates regeneration of CST and/or rubrospinal pathways.
The authors also show evidence for the presence of FGF2
induced fibronectin positive cells that fill the cystic cavities
and allow neurons to grow into the injury site. However, the
authors do not show any immunohistochemistry that would
show direct evidence of axon growth through the lesion
site. The locomotor improvement observed in the BBB does
not necessarily indicate regeneration of axons but could also
result from changes in the lumbar central pattern generators
(CPGs).
Another group investigated the effect of FGF2 on the
immune reaction in mice [74]. They injected FGF2 subcu-
taneously during two weeks after a T12 lateral hemisection.
Comparable to the already discussed studies they found a
locomotor improvement of the animals treated with FGF2
as assessed by the grid test and the mouse-modified open
field test for mice (mBBB). Further, they discovered that
the mRNA level of the proinflammatory factor TNF𝛼 is
reduced at the lesion site leading to decreased microglia
and macrophage activation. While they did not observe
lower total numbers of astrocytes they found fewer acti-
vated astrocytes which they believe led to less abundant
CSPG as they observed it. Furthermore, they showed that
FGF2 mediated astrocyte bipolar morphology, which leads
to astrocytic bridges through the lesion site onto which
growing nerve fibres can follow, as has been shown earlier
in zebrafish [98] and rats [76]. This study shows that FGF2
treatment also affects the immune reaction after SCI. This
in turn opens the question if the studies discussed above
elicited also a differential immune response depending on the
addition of FGF2 or not. Also, the question remains whether
administering FGF2 via injection, either into the spinal cord
or subcutaneously, raises a different immune response then
applying a fibrin matrix that contains the ligand. Certainly
it seems to be more feasible to inject FGF2 subcutaneously
rather than intraspinally.
The group of de Oliveira Costa used gel foam containing
sciatic nerve fragments plus FGF2 or PBS to bridge a T10
complete transection in rats [75]. They found that there is
a therapeutic effect of the sciatic nerve fragment transplan-
tation itself that could be increased only in some behaviour
tests by the addition of FGF2.They showed that rats that were
transplanted with nerve fragments reached score four and
rats that only had the gel foam implanted reached score one
on the BBB scale eight weeks after injury. Furthermore, ani-
mals that received the nerve graft containing FGF2 reached
score six in the BBB test. However, in the combined behaviour
score (CBS) test there was no therapeutic effect between the
group with the nerve transplant only and the group with
the nerve transplant plus FGF2, and both groups showed
a significant effect compared to gel foam only transplanted
animals. The studies discussed here show that FGF2 has
the potential to promote growth of axons. They also show
that FGF2 alters the immune response which might have an
influence on the axon regeneration. We believe that these
studies also exemplify that the timing and route of application
is important, as made apparent by the two studies with
Schwann cell grafts that had very differential outcomes.
We have so far discussed that FGF1 and FGF2 induce
regeneration of axons when applied either alone or in
combination with a nerve- or cellular bridges. Next, we will
discuss combination therapies that either combine intrinsic
and extrinsic effects or different effects of FGF ligands.
A summary of FGF2 dependent therapies can be found in
Table 2.
4.3. Combination Therapy. The functional effects that are
achieved by the presented strategies are mostly positive;
however they are small and it has to be the aim to get
even better effects that might be translatable. One approach
should be to combine intrinsic neuronal effects with extrinsic
effects. The groups of Lee and Silver performed such a
combinatorial study [76] and this will be discussed in more
detail here. They used the approach developed by Cheng
et al. However, they included an experimental group that
received Chondrointinase ABC (ChABC) in addition to
peripheral nerve grafts (PNGs) and FGF1 (PNGs + FGF1
+ ChABC) [76]. ChABC is a bacterial enzyme that cleaves
the inhibitory sugar chains of the CSPGs [99]. The authors
bridged the injury gap with 18 intercostal nerve segments to
produce PNGs, soaked the PNGs with ChABC, and covered
them with an FGF1-laden fibrin matrix. Furthermore, they
injected ChABC into the interface of graft and host. This
study focused solely on the regeneration of bladder function.
8 Neural Plasticity
Table 2: Different strategies to promote regeneration or neuroprotection using FGF2.
Species Model Therapeutic intervention Outcome Control Ref
Rat
Complete transection at
T9/T10.
Removal of 4mm of SC
Rat Schwann cell grafts
with FGF2 fibrin glue
Increased survival of NeuN
positive cells
Schwann cell graft
without FGF2
[70]
Rat Moderate contusion
injury at T10
Osmotic minipump in the
lateral ventricle and lumbar
thecae sac releasing FGF2
30min after injury for 1
week
Improvement of BBB score
from 12/13 to 15/16. More
tissue sparing
Osmotic minipump
releasing bovine serum
albumin
[71]
Rat Severe contusion injury
at T10
Osmotic minipump in the
lateral ventricle and lumbar
thecae sac releasing FGF2
30min after injury for 1
week
Improvement of BBB score
from 7–10 to 10–13
Osmotic minipump
releasing bovine serum
albumin
[72]
Rat Complete Transection at
T10
Direct injection of FGF2
into the surrounding tissue
of injury
Improvement of BBB score
from 0 to 6 Injection of vehicle
[73]
Mouse T12 hemisection Subcutaneous injection ofFGF2 during 2 weeks
Better performance on the
grid test and mBBB.
Reduced level of TNF𝛼
leading to decreased
microglia and macrophage
activation
Injection of vehicle [74]
Rat T10 complete transection
Bridging with gel foam
containing sciatic nerve
fragments and FGF2
Improvement in BBB from
1 to 6
Bridging with gel foam
containing sciatic nerve
fragments and PBS
[75]
They showed that the transection + PNG + FGF1+ ChABC
treated animals (experimental group) had significantly better
bladder function than all five control groups (laminectomy
only, transection only, transection + PNG, transection +
FGF1 + ChABC, transection + PNG + FGF1, transection +
PNG + ChABC). Importantly, they found that transection
+ PNG + FGF1 and transection + PNG + ChABC groups
had significantly better bladder functions than the other
control groups, but not as good as the experimental group.
In addition they showed that serotonin (5-HT) and tyrosine
hydroxylase (TH) positive fibers, both important for urina-
tion (micturition), had extended into the bridge, across the
caudal PNG/spinal cord interface and well into the caudal
cord [76]. This phenomenon was also present in the PNG +
FGF1 treated animals, but again to a lesser extent than the
PNG + FGF1 + ChABC animals. Injections of a retrograde
tracer below the bridge in the L4 spinal cord segment showed
that in both groups fibres of the D-region (important for
micturition), raphe magnus nuclei, reticular formation, and
the cervical spinal cord extended into the host tissue caudal to
the bridge. However, PNG + FGF1 + ChABC treated animals
showed more labelled cells and in more neural populations
than did the PNG + FGF1 group. Furthermore, as mentioned
before, they showed that astrocytes aligned at the interface
of PNG and host and they had indications that it was at
these sites of astrocyte alignment where axons entered the
distal cord [76]. Since this study has been so extensively
controlledwith five control groups theywere able to show that
the combination of carefully chosen factors can increase the
beneficial effect of therapies.
A different approach of exploring synergism between
treatments was taken by ourselves. We hoped to combine the
different effects that the various FGF ligands had by overex-
pressing their common receptor, the FGFR1 [77]. We did that
in a rat model of unilateral pyramidotomy. We injected an
AAV serotype 1 overexpressing either the FGFR1 or mCherry
as control one week prior to the injury into the sensorimotor
cortex supplying theCST that will be left intact. After injuring
the contralateral CST with a pyramidotomy we assessed the
animals behaviourally by the horizontal ladder with unevenly
spaced rungs and the Montoya staircase test. In addition,
we investigated sprouting of the intact contralateral CST
fibres that overexpressed FGFR1 or mCherry, over the spinal
midline in the cervical cord. However, in all our tests we did
not find a difference between control and FGFR1 overexpress-
ing animals. Furthermore, we investigated overexpression of
FGFR1 in vitro in cerebellar granule neurons and we found
that overexpression of FGFR1 results in decreased neurite
outgrowth compared to control cells overexpressing GFP.We
hypothesis that this effect is due to the sequestering of adaptor
proteins, such as FRS2, away from other proregenerative
pathways, such as NGF-TRKA signalling. It has been shown
by others that overexpressed FGFR1 sequestering adaptor
proteins away from other proneurite outgrowth pathways
[100] and that FGF2 can have an inhibitory effect on neurite
outgrowth in cerebellar neurons growing on monolayers of
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Table 3: Combination therapy.
Species Model Therapeutic intervention Outcome Control Ref
Rat T10 completetransection
18 intercostal segments
(peripheral nerve autografts
(PNGs)) soaked with ChABC
and covered by FGF1-laden
fibrin matrix, plus ChABC
injection in the interface of
graft and host.
Significantly better bladder
function.
Regeneration of 5-HT and
TH positive fibres into and
beyond the graft
Laminectomy only.
Transection only.
Transection plus PNG.
Transection plus FGF1 and
ChABC.
Transection plus PNG and
ChABC.
Transection plus PNG
[76]
Rat Unilateralpyramidotomy
Overexpression of FGFR1 via
AAV1 injections into the
unlesioned CST
No difference between
FGFR1 overexpressing
animals and control
animals
Injection of AAV1
overexpressing mCherry [77]
cortical astrocytes [101]. This last study exemplifies that com-
bining unfavourable or antagonistic factors can be counter-
productive.
Several groups have shown that combination therapies
involving grafts bridging the injury site and addition of FGF1
or 2 and possibly other factors can improve outcome even
after severe spinal cord injury.
Combination therapies are summarized in Table 3.
5. Conclusion
Most FGFR signalling related therapies discussed in this
review show potential to improve plasticity and result in
enhanced axon growth and improvement of motor related
functions. However, the achieved improvements are small
and need to be enhanced. This might be achieved by using
combined therapies as we have illustrated in this review
with the work of Lee et al. It is evident that combina-
tion of proregenerative strategies can increase the observed
motor improvements, but again the benefits are limited and
often only confined to specific outcomes and not a general
phenomenon. We therefore believe that there is a need to
understand the distinct effects better to combine therapies in
a better temporal and spatial manner.
The disadvantages of most of the described studies is that
they use highly invasive FGF application techniques, often
involving autologous transplantation that results in multiple
invasive procedures. We believe that the focus should shift
towardsmore translatable techniques; however, it is clear that
this is not trivial for a ligand that should be delivered very
locally in high concentrations over a period of time. We,
ourselves, have tried one alternative approach by injecting
into the motor cortex adeno associated viruses (AAVs), a
delivery method with the advantage of being already used
in humans, however, still rather invasive [77]. Unfortunately,
this treatment showed no beneficial effects. A possible out-
come improvement strategy for this and other studies might
be the combined overexpression of the FGF receptor and
ligand as opposed to our study which only used overexpres-
sion of the FGFR1. Another veryminimally invasive approach
has been chosen by Goldshmit et al. which performed a
successful study with subcutaneous FGF injections [74]. This
benefits from the fact that the blood-brain-barrier (BBB) is
open due to the injury and the injected FGF can reach the
injury site. However, it is not clear if the opening of the BBB
correlates with the optimal FGF treating window and this
strategy will not allow a more prolonged FGF treatment. A
possible disadvantage of systemic application of FGF might
be unexpected adverse side effects. This has so far not been
investigated in context with spinal cord injury treatment.The
invasive, but local delivery of FGF ligands, has so far not
led to major adverse side effects; however, a more global
treatment with FGF ligands could result in a wide range
of problems, since the FGFR pathway has so many diverse
functions in the whole organism and plays an important role
in the progression of cancer.
All these studies used different FGF delivery methods
(though most of them use slow-release matrices) and differ-
ent time regimes and injury models. This makes it difficult
to compare them directly. It has been discussed before that
different studies will lead to different outcomes mainly due
to the experimental set-up rather than true regenerative
potentials [102].
Most studies focused on improving the motor outcome
after treatment and only very few report observations on
regeneration of sensory fibres. It would therefore, for the
future, be interesting to shed some light on the regeneration
of sensory fibres after FGF treatment since both, sensory and
motor fibres, need to regenerate for clinical improvement.
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